Glioblastoma

Clinical Overview

Glioblastoma (GBM) is the most aggressive primary brain tumor with median survival of 15 months despite maximal therapy including surgical resection, radiation, and temozolomide chemotherapy. ctDNA detection in GBM presents a unique challenge: the blood-brain barrier (BBB) significantly restricts tumor DNA shedding into peripheral circulation, resulting in markedly lower plasma detection rates compared to other solid tumors.

Cerebrospinal fluid (CSF) ctDNA offers superior sensitivity due to direct contact with the central nervous system. CSF detection rates range from 49-100% depending on study design and tumor grade, compared to plasma detection of 37.5-88% with targeted approaches. Variant allele frequencies are substantially higher in CSF than in plasma, reflecting the BBB's profound impact on peripheral blood-based monitoring.

CSF vs Plasma ctDNA Detection: Critical Comparison

The blood-brain barrier fundamentally limits plasma ctDNA detection in glioblastoma. Multiple studies demonstrate CSF's superior sensitivity for detecting tumor-derived mutations, with significantly higher variant allele frequencies enabling more reliable monitoring.

*Note: CSF detection rates vary by study design and patient selection (49% in Miller et al. 2019 mixed glioma cohort; higher in GBM-enriched cohorts). **Note: Plasma detection up to 84-88% achieved with ddPCR for specific mutations (Jones et al. 2024, n=110); lower rates with standard NGS methods.

ctDNA Testing Methodology

The blood-brain barrier (BBB) is the central challenge for ctDNA detection in GBM. Plasma ctDNA shedding is significantly reduced compared to systemic cancers, with standard methods detecting ctDNA in only 37.5% of plasma samples. Advanced targeted methods (e.g., ddPCR detecting variants at allele frequencies as low as 0.01%) can overcome some BBB limitations but cannot match CSF sensitivity for comprehensive profiling. Key GBM mutations tracked include TERT promoter, IDH1/2, EGFR, and TP53.

Sample Type Selection

CSF sampling requires lumbar puncture but provides superior detection rates (49-100% depending on study and tumor grade). Plasma sampling is less invasive but significantly limited by the BBB, with detection rates ranging from 37.5% (standard methods) to 84-88% for individual mutations using ddPCR (Jones et al. 2024).

MRD Detection Clinical Utility

Plasma ctDNA Detection Rates

Detection rates in plasma vary significantly based on methodology and disease burden:

Reference: Jones JJ et al. demonstrated 84-88% plasma ctDNA detection for key glioma mutations (IDH1, TERTp) using ddPCR in 110 glioma patients. A separate study by the same group showed plasma ctDNA enables early detection of temozolomide resistance mutations (Neuro-Oncol Adv 2024;6(1):vdae027 and vdae041).

CSF ctDNA Detection Rates

CSF consistently demonstrates superior detection across multiple studies:

Longitudinal CSF Monitoring

2025 Systematic Review and Meta-Analysis: CSF ctDNA

Treatment Response Monitoring

ctDNA changes correlate with radiographic response in GBM patients undergoing therapy. Declining ctDNA levels indicate treatment response, while rising levels precede radiographic progression. However, the BBB limitation means plasma ctDNA may remain undetectable even in active disease, particularly with low tumor burden or intact BBB.

Clinical utility limited by: Pseudoprogression on imaging can complicate interpretation, and plasma ctDNA negativity does not exclude active disease due to BBB restrictions.

Genotyping Clinical Utility

IDH1/2 Mutations

IDH1/2 mutations occur in approximately 5% of primary glioblastomas but are more common in secondary GBM and lower-grade gliomas that progress to GBM. These mutations are associated with improved prognosis and represent actionable therapeutic targets.

Clinical significance: While vorasidenib demonstrates strong efficacy in lower-grade IDH-mutant gliomas, its role in IDH-mutant glioblastoma requires further study. ctDNA can identify IDH mutations non-invasively, but treatment decisions should be based on tissue-confirmed diagnosis and grade.

EGFR and EGFRvIII

EGFR amplification occurs in approximately 40% of GBM, and the EGFRvIII deletion variant is present in 25-30% of EGFR-amplified tumors. Despite being common and targetable mutations, EGFR inhibitors have not demonstrated clinical efficacy in GBM.

Clinical limitation: While ctDNA can detect EGFR mutations, no effective EGFR-targeted therapies currently exist for GBM due to BBB penetration issues. The BBB that limits ctDNA release also prevents most small molecule inhibitors from reaching therapeutic concentrations in brain tumors.

MGMT Promoter Methylation

MGMT promoter methylation status is the strongest predictive biomarker for temozolomide chemotherapy response in GBM. Methylation silences the MGMT DNA repair enzyme, rendering tumors more sensitive to alkylating chemotherapy.

TERT Promoter Mutations

TERT promoter mutations occur in approximately 80% of primary glioblastomas and are associated with telomerase activation and aggressive biology.

Clinical Summary

Bottom Line: The blood-brain barrier fundamentally limits plasma ctDNA detection in glioblastoma, with CSF offering superior sensitivity across multiple studies. Advanced ddPCR methods improve plasma detection to 84-88% for specific mutations (IDH1, TERTp), but the substantially lower VAF in plasma compared to CSF means negative plasma results cannot exclude active disease. Molecular profiling via ctDNA can identify actionable targets such as IDH mutations and MGMT methylation status, but therapeutic options remain limited by the same BBB that restricts ctDNA shedding.